Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
High mobility group protein HMGA2 (HMGA2) is a non-histone chromosomal protein that functions as an architectural transcription factor by binding to AT-rich DNA sequences in the minor groove via its three 'AT-hook' motifs [NIH, Wikipedia]. This binding induces conformational changes in DNA, facilitating the assembly of enhanceosomes and regulating the expression of genes involved in cell growth, differentiation, and the cell cycle [NIH, Ma'ayan Laboratory]. HMGA2 is predominantly expressed during embryonic development and is largely absent in adult tissues, but its aberrant re-expression is a hallmark of many human malignancies, including breast, lung, and ovarian cancers [NIH]. In cancer, it promotes epithelial-mesenchymal transition (EMT), enhances cell proliferation, and confers resistance to apoptosis and DNA-damaging agents [NIH]. Beyond oncology, HMGA2 plays a critical role in adipogenesis and is associated with obesity, human height, and benign tumors such as lipomas [NIH, UniProt]. It also participates in DNA repair mechanisms, including base excision repair, which can contribute to chemotherapy resistance in tumor cells [NIH, Wikipedia]. Therapeutic targeting of HMGA2 is being explored through DNA minor groove binders like netropsin, which inhibit its DNA-binding activity [NIH]. Additionally, RNA-based strategies like let-7 mimics or siRNAs are being investigated to restore natural post-transcriptional repression or silence its oncogenic activity [NIH, Ma'ayan Laboratory]. HMGA2's role as a master regulator of stemness and its specific expression pattern make it an attractive diagnostic and prognostic biomarker in various clinical settings [NIH, 2BScientific].
Inhibition of DNA binding through minor groove competition; post-transcriptional gene silencing via miRNA mimics or siRNA; indirect suppression through inhibition of upstream signaling pathways like STAT3/Lin28.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on High mobility group protein HMGA2 (HMGA2) (HMGA2).